;PMID: 9365186
;source_file_1782.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..52] = [t:0..52]
;1)sentence:[e:58..149] = [t:58..149]
;2)section:[e:153..222] = [t:153..222]
;3)section:[e:226..327] = [t:226..327]
;4)sentence:[e:331..718] = [t:331..718]
;5)sentence:[e:720..866] = [t:720..866]
;6)sentence:[e:867..1003] = [t:867..1003]
;7)sentence:[e:1004..1229] = [t:1004..1229]
;8)sentence:[e:1230..1375] = [t:1230..1375]
;9)sentence:[e:1376..1619] = [t:1376..1619]
;10)sentence:[e:1620..1755] = [t:1620..1755]
;11)sentence:[e:1756..1926] = [t:1756..1926]
;12)sentence:[e:1927..2104] = [t:1927..2104]
;13)section:[e:2108..2152] = [t:2108..2152]

;section 0 Span:0..52
;J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):157-66.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem)
        (NNP:[18..21] Mol) (NNP:[22..26] Biol) (IN:[26..27] .)
        (CD:[28..32] 1997) (.:[33..39] Apr;61) (-LRB-:[39..40] -LRB-)
        (JJ:[40..42] 3-) (CD:[42..43] 6) (-RRB-:[43..44] -RRB-)
        (CD:[44..48] :157) (::[48..49] -) (CD:[49..51] 66) (.:[51..52] .)))

;sentence 1 Span:58..149
;Effect of estrogen deprivation on the reproductive physiology of male and
;female  primates.
;[68..76]:substance:"estrogen"
(SENT
  (NP-HLN
    (NP (NN:[58..64] Effect))
    (PP (IN:[65..67] of)
      (NP (NN:[68..76] estrogen) (NN:[77..88] deprivation)))
    (PP (IN:[89..91] on)
      (NP
        (NP (DT:[92..95] the) (JJ:[96..108] reproductive)
            (NN:[109..119] physiology))
        (PP (IN:[120..122] of)
          (NP
            (NP (JJ:[123..127] male)
              (NML-1 (-NONE-:[127..127] *P*)))
            (CC:[128..131] and)
            (NP (JJ:[132..138] female)
              (NML-1 (NNS:[140..148] primates)))))))
    (.:[148..149] .)))

;section 2 Span:153..222
;Shetty G, Krishnamurthy H, Krishnamurthy HN, Bhatnagar S, Moudgal RN.
(SEC
  (FRAG (NNP:[153..159] Shetty) (NNP:[160..161] G) (,:[161..162] ,)
        (NNP:[163..176] Krishnamurthy) (NNP:[177..179] H,)
        (NNP:[180..193] Krishnamurthy) (NNP:[194..196] HN) (,:[196..197] ,)
        (NNP:[198..207] Bhatnagar) (NNP:[208..209] S) (,:[209..210] ,)
        (NNP:[211..218] Moudgal) (NNP:[219..221] RN) (.:[221..222] .)))

;section 3 Span:226..327
;Center for Reproductive Biology and Molecular Endocrinology, Indian Institute
;of  Science, Bangalore.
(SEC
  (FRAG (NNP:[226..232] Center) (IN:[233..236] for)
        (NNP:[237..249] Reproductive) (NNP:[250..257] Biology)
        (CC:[258..261] and) (NNP:[262..271] Molecular)
        (NNP:[272..285] Endocrinology) (,:[285..286] ,) (NNP:[287..293] Indian)
        (NNP:[294..303] Institute) (IN:[304..306] of) (NNP:[308..315] Science)
        (,:[315..316] ,) (NNP:[317..326] Bangalore) (.:[326..327] .)))

;sentence 4 Span:331..718
;The availability of CGS 16949A, CGS 20267 and CGP 47645, a series of
;aromatase  inhibitors (AIs) having high specific activity and specificity,
;made possible  this study wherein the need for estrogen (E) for regulating
;(a) follicular  maturation/ovulation, luteal function and pregnancy
;establishment, and (b)  testicular function of the bonnet monkey (Macaca
;radiata) has been examined.
;[351..361]:substance:"CGS 16949A"
;[363..372]:substance:"CGS 20267"
;[377..386]:substance:"CGP 47645"
;[400..421]:substance:"aromatase  inhibitors"
;[423..426]:substance:"AIs"
;[522..530]:substance:"estrogen"
;[532..533]:substance:"E"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[331..334] The) (NN:[335..347] availability))
      (PP (IN:[348..350] of)
        (NP
          (NP
            (NP (NN:[351..354] CGS) (NN:[355..361] 16949A))
            (,:[361..362] ,)
            (NP (NN:[363..366] CGS) (CD:[367..372] 20267))
            (CC:[373..376] and)
            (NP (NN:[377..380] CGP) (CD:[381..386] 47645)))
          (,:[386..387] ,)
          (NP
            (NP (DT:[388..389] a) (NN:[390..396] series))
            (PP (IN:[397..399] of)
              (NP
                (NP
                  (NP (NN:[400..409] aromatase) (NNS:[411..421] inhibitors))
                  (NP (-LRB-:[422..423] -LRB-) (NNS:[423..426] AIs)
                      (-RRB-:[426..427] -RRB-)))
                (VP (VBG:[428..434] having)
                  (NP
                    (NP
                      (ADJP-1 (JJ:[435..439] high))
                      (JJ:[440..448] specific) (NN:[449..457] activity))
                    (CC:[458..461] and)
                    (NP
                      (ADJP-1 (-NONE-:[461..461] *P*))
                      (NN:[462..473] specificity))))))))))
    (,:[473..474] ,)
    (VP (VBD:[475..479] made)
      (S
        (NP-SBJ-3 (-NONE-:[479..479] *ICH*))
        (ADJP-PRD (JJ:[480..488] possible))
        (NP-3
          (NP (DT:[490..494] this) (NN:[495..500] study))
          (SBAR
            (WHPP (IN:[501..508] wherein))
            (S
              (NP-SBJ-2
                (NP (DT:[509..512] the) (NN:[513..517] need))
                (PP (IN:[518..521] for)
                  (NP
                    (NP (NN:[522..530] estrogen))
                    (NP (-LRB-:[531..532] -LRB-) (NN:[532..533] E)
                        (-RRB-:[533..534] -RRB-))))
                (PP (IN:[535..538] for)
                  (S-NOM
                    (NP-SBJ (-NONE-:[538..538] *))
                    (VP (VBG:[539..549] regulating)
                      (NP
                        (NP
                          (LST (LS:[550..553] -LRB-a-RRB-))
                          (NP
                            (NP (JJ:[554..564] follicular)
                                (NN:[566..576] maturation))
                            (SYM:[576..577] /)
                            (NP (NN:[577..586] ovulation)))
                          (,:[586..587] ,)
                          (NP (JJ:[588..594] luteal) (NN:[595..603] function))
                          (CC:[604..607] and)
                          (NP (NN:[608..617] pregnancy)
                              (NN:[618..631] establishment)))
                        (,:[631..632] ,) (CC:[633..636] and)
                        (NP
                          (LST (LS:[637..640] -LRB-b-RRB-))
                          (NP
                            (NP (JJ:[642..652] testicular)
                                (NN:[653..661] function))
                            (PP (IN:[662..664] of)
                              (NP
                                (NP (DT:[665..668] the) (NN:[669..675] bonnet)
                                    (NN:[676..682] monkey))
                                (NP (-LRB-:[683..684] -LRB-)
                                    (NNP:[684..690] Macaca)
                                    (NNP:[691..698] radiata)
                                    (-RRB-:[698..699] -RRB-)))))))))))
              (VP (VBZ:[700..703] has)
                (VP (VBN:[704..708] been)
                  (VP (VBN:[709..717] examined)
                    (NP-2 (-NONE-:[717..717] *))))))))))
    (.:[717..718] .)))

;sentence 5 Span:720..866
;Generally these compounds, used in the range of 500 microg to 2.5 mg/day did
;not  inhibit follicular maturation although they did reduce E levels.
;[736..745]:substance:"compounds"
;[768..771]:quantitative-value:"500"
;[772..778]:quantitative-units:"microg"
;[782..785]:quantitative-value:"2.5"
;[786..792]:quantitative-units:"mg/day"
;[857..858]:substance:"E"
(SENT
  (S
    (ADVP (RB:[720..729] Generally))
    (NP-SBJ
      (NP (DT:[730..735] these) (NNS:[736..745] compounds))
      (,:[745..746] ,)
      (VP (VBN:[747..751] used)
        (NP (-NONE-:[751..751] *))
        (PP (IN:[752..754] in)
          (NP
            (NP (DT:[755..758] the) (NN:[759..764] range))
            (PP (IN:[765..767] of)
              (NP
                (NP
                  (QP (CD:[768..771] 500) (NN:[772..778] microg)
                      (TO:[779..781] to) (CD:[782..785] 2.5))
                  (NN:[786..788] mg))
                (PP (SYM:[788..789] /)
                  (NP (NN:[789..792] day)))))))))
    (VP (VBD:[793..796] did) (RB:[797..800] not)
      (VP (VB:[802..809] inhibit)
        (NP (JJ:[810..820] follicular) (NN:[821..831] maturation))
        (SBAR-ADV (IN:[832..840] although)
          (S
            (NP-SBJ (PRP:[841..845] they))
            (VP (VBD:[846..849] did)
              (VP (VB:[850..856] reduce)
                (NP (NN:[857..858] E) (NNS:[859..865] levels))))))))
    (.:[865..866] .)))

;sentence 6 Span:867..1003
;Although low  doses had no effect on ovulation it appears that relatively
;high doses of CGS  20267 and CGP 47645 could be inhibiting it.
;[955..965]:substance:"CGS  20267"
;[970..979]:substance:"CGP 47645"
(SENT
  (S
    (SBAR-ADV (IN:[867..875] Although)
      (S
        (NP-SBJ (JJ:[876..879] low) (NNS:[881..886] doses))
        (VP (VBD:[887..890] had)
          (NP
            (NP (DT:[891..893] no) (NN:[894..900] effect))
            (PP (IN:[901..903] on)
              (NP (NN:[904..913] ovulation)))))))
    (NP-SBJ (PRP:[914..916] it))
    (VP (VBZ:[917..924] appears)
      (SBAR (IN:[925..929] that)
        (S
          (NP-SBJ
            (NP
              (ADJP (RB:[930..940] relatively) (JJ:[941..945] high))
              (NNS:[946..951] doses))
            (PP (IN:[952..954] of)
              (NP
                (NP (NN:[955..958] CGS) (CD:[960..965] 20267))
                (CC:[966..969] and)
                (NP (NN:[970..973] CGP) (CD:[974..979] 47645)))))
          (VP (MD:[980..985] could)
            (VP (VB:[986..988] be)
              (VP (VBG:[989..999] inhibiting)
                (NP (PRP:[1000..1002] it))))))))
    (.:[1002..1003] .)))

;sentence 7 Span:1004..1229
;Three oral doses of letrozole (CGS  20267, each dose of 2 mg) during the
;follicular phase resulted in the formation  of multiple follicles in cycling
;females, and these could be ovulated by  exogenous hCG (1000 IU) treatment.
;[1024..1033]:substance:"letrozole"
;[1035..1045]:substance:"CGS  20267"
;[1060..1061]:quantitative-value:"2"
;[1062..1064]:quantitative-units:"mg"
;[1205..1208]:substance:"hCG"
;[1210..1214]:quantitative-value:"1000"
;[1215..1217]:quantitative-units:"IU"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (CD:[1004..1009] Three) (JJ:[1010..1014] oral)
            (NNS:[1015..1020] doses))
        (PP (IN:[1021..1023] of)
          (NP (NN:[1024..1033] letrozole)))
        (PRN (-LRB-:[1034..1035] -LRB-)
          (FRAG
            (NP (NN:[1035..1038] CGS) (CD:[1040..1045] 20267))
            (,:[1045..1046] ,)
            (NP
              (NP (DT:[1047..1051] each) (NN:[1052..1056] dose))
              (PP (IN:[1057..1059] of)
                (NP (CD:[1060..1061] 2) (NN:[1062..1064] mg)))))
          (-RRB-:[1064..1065] -RRB-))
        (PP-TMP (IN:[1066..1072] during)
          (NP (DT:[1073..1076] the) (JJ:[1077..1087] follicular)
              (NN:[1088..1093] phase))))
      (VP (VBD:[1094..1102] resulted)
        (PP-CLR (IN:[1103..1105] in)
          (NP
            (NP (DT:[1106..1109] the) (NN:[1110..1119] formation))
            (PP (IN:[1121..1123] of)
              (NP (JJ:[1124..1132] multiple) (NNS:[1133..1142] follicles)))))
        (PP-LOC (IN:[1143..1145] in)
          (NP (VBG:[1146..1153] cycling) (NNS:[1154..1161] females)))))
    (,:[1161..1162] ,) (CC:[1163..1166] and)
    (S
      (NP-SBJ-1 (DT:[1167..1172] these))
      (VP (MD:[1173..1178] could)
        (VP (VB:[1179..1181] be)
          (VP (VBN:[1182..1190] ovulated)
            (NP-1 (-NONE-:[1190..1190] *))
            (PP-MNR (IN:[1191..1193] by)
              (NP (JJ:[1195..1204] exogenous) (NN:[1205..1208] hCG)
                (PRN (-LRB-:[1209..1210] -LRB-)
                  (NP (CD:[1210..1214] 1000) (NN:[1215..1217] IU))
                  (-RRB-:[1217..1218] -RRB-))
                (NN:[1219..1228] treatment)))))))
    (.:[1228..1229] .)))

;sentence 8 Span:1230..1375
;Although administration of AI during the  early luteal phase had no effect on
;progesterone (P) production, it prevented  pregnancy establishment.
;[1257..1259]:substance:"AI"
;[1308..1320]:substance:"progesterone"
;[1322..1323]:substance:"P"
(SENT
  (S
    (SBAR-ADV (IN:[1230..1238] Although)
      (S
        (NP-SBJ
          (NP (NN:[1239..1253] administration))
          (PP (IN:[1254..1256] of)
            (NP (NN:[1257..1259] AI)))
          (PP-TMP (IN:[1260..1266] during)
            (NP (DT:[1267..1270] the) (JJ:[1272..1277] early)
                (JJ:[1278..1284] luteal) (NN:[1285..1290] phase))))
        (VP (VBD:[1291..1294] had)
          (NP
            (NP (DT:[1295..1297] no) (NN:[1298..1304] effect))
            (PP (IN:[1305..1307] on)
              (NP
                (NML
                  (NML (NN:[1308..1320] progesterone))
                  (NML (-LRB-:[1321..1322] -LRB-) (NN:[1322..1323] P)
                       (-RRB-:[1323..1324] -RRB-)))
                (NN:[1325..1335] production)))))))
    (,:[1335..1336] ,)
    (NP-SBJ (PRP:[1337..1339] it))
    (VP (VBD:[1340..1349] prevented)
      (NP (NN:[1351..1360] pregnancy) (NN:[1361..1374] establishment)))
    (.:[1374..1375] .)))

;sentence 9 Span:1376..1619
;Whereas AI administration in the female had no  significant effect on
;luteinizing hormone (LH) and follicle stimulating hormone  (FSH) levels
;(except at high drug dosages), it significantly increased serum  testosterone
;(T) levels in the male.
;[1384..1386]:substance:"AI"
;[1446..1465]:substance:"luteinizing hormone"
;[1467..1469]:substance:"LH"
;[1475..1503]:substance:"follicle stimulating hormone"
;[1506..1509]:substance:"FSH"
;[1534..1538]:substance:"drug"
;[1583..1595]:substance:"testosterone"
;[1597..1598]:substance:"T"
(SENT
  (S
    (SBAR-ADV (IN:[1376..1383] Whereas)
      (S
        (NP-SBJ
          (NP (NN:[1384..1386] AI) (NN:[1387..1401] administration))
          (PP-LOC (IN:[1402..1404] in)
            (NP (DT:[1405..1408] the) (NN:[1409..1415] female))))
        (VP (VBD:[1416..1419] had)
          (NP
            (NP (DT:[1420..1422] no) (JJ:[1424..1435] significant)
                (NN:[1436..1442] effect))
            (PP (IN:[1443..1445] on)
              (NP
                (NP
                  (NML
                    (NML (VBG:[1446..1457] luteinizing)
                         (NN:[1458..1465] hormone))
                    (NML (-LRB-:[1466..1467] -LRB-) (NN:[1467..1469] LH)
                         (-RRB-:[1469..1470] -RRB-)))
                  (NML-1 (-NONE-:[1470..1470] *P*)))
                (CC:[1471..1474] and)
                (NP
                  (NML
                    (NML (NN:[1475..1483] follicle)
                         (VBG:[1484..1495] stimulating)
                         (NN:[1496..1503] hormone))
                    (NML (-LRB-:[1505..1506] -LRB-) (NN:[1506..1509] FSH)
                         (-RRB-:[1509..1510] -RRB-)))
                  (NML-1 (NNS:[1511..1517] levels)))))
            (PRN (-LRB-:[1518..1519] -LRB-)
              (PP (IN:[1519..1525] except)
                (PP (IN:[1526..1528] at)
                  (NP (JJ:[1529..1533] high) (NN:[1534..1538] drug)
                      (NNS:[1539..1546] dosages))))
              (-RRB-:[1546..1547] -RRB-))))))
    (,:[1547..1548] ,)
    (NP-SBJ (PRP:[1549..1551] it))
    (ADVP-MNR (RB:[1552..1565] significantly))
    (VP (VBD:[1566..1575] increased)
      (NP (NN:[1576..1581] serum)
        (NML
          (NML (NN:[1583..1595] testosterone))
          (NML (-LRB-:[1596..1597] -LRB-) (NN:[1597..1598] T)
               (-RRB-:[1598..1599] -RRB-)))
        (NNS:[1600..1606] levels))
      (PP-LOC (IN:[1607..1609] in)
        (NP (DT:[1610..1613] the) (NN:[1614..1618] male))))
    (.:[1618..1619] .)))

;sentence 10 Span:1620..1755
;Sustained high levels of T (30-50 ng/ml)  could be maintained for 100 days by
;administering 2.5 mg of CGP 47465 orally  once in 5 days.
;[1645..1646]:substance:"T"
;[1648..1653]:quantitative-value:"30-50"
;[1654..1659]:quantitative-units:"ng/ml"
;[1686..1689]:quantitative-value:"100"
;[1690..1694]:quantitative-units:"days"
;[1712..1715]:quantitative-value:"2.5"
;[1716..1718]:quantitative-units:"mg"
;[1722..1731]:substance:"CGP 47465"
;[1748..1749]:quantitative-value:"5"
;[1750..1754]:quantitative-units:"days"
(SENT
  (S
    (NP-SBJ-1
      (NP (VBN:[1620..1629] Sustained) (JJ:[1630..1634] high)
          (NNS:[1635..1641] levels))
      (PP (IN:[1642..1644] of)
        (NP (NN:[1645..1646] T)))
      (PP (-LRB-:[1647..1648] -LRB-)
        (NP
          (NP
            (QP (CD:[1648..1650] 30) (HYPH:[1650..1651] -) (CD:[1651..1653] 50))
            (NN:[1654..1656] ng))
          (PP (SYM:[1656..1657] /)
            (NP (NN:[1657..1659] ml))))
        (-RRB-:[1659..1660] -RRB-)))
    (VP (MD:[1662..1667] could)
      (VP (VB:[1668..1670] be)
        (VP (VBN:[1671..1681] maintained)
          (NP-1 (-NONE-:[1681..1681] *))
          (PP (IN:[1682..1685] for)
            (NP (CD:[1686..1689] 100) (NNS:[1690..1694] days)))
          (PP-MNR (IN:[1695..1697] by)
            (S-NOM
              (NP-SBJ (-NONE-:[1697..1697] *))
              (VP (VBG:[1698..1711] administering)
                (NP
                  (NP (CD:[1712..1715] 2.5) (NN:[1716..1718] mg))
                  (PP (IN:[1719..1721] of)
                    (NP (NN:[1722..1725] CGP) (CD:[1726..1731] 47465))))
                (ADVP-MNR (RB:[1732..1738] orally))
                (ADVP-TMP (RB:[1740..1744] once)
                  (PP (IN:[1745..1747] in)
                    (NP (CD:[1748..1749] 5) (NNS:[1750..1754] days))))))))))
    (.:[1754..1755] .)))

;sentence 11 Span:1756..1926
;Blockade of E synthesis in the male led to the disruption of  testicular germ
;cell transformation, which in turn resulted in a significant  reduction in
;sperm production.
;[1768..1769]:substance:"E"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1756..1764] Blockade))
      (PP (IN:[1765..1767] of)
        (NP (NN:[1768..1769] E) (NN:[1770..1779] synthesis)))
      (PP-LOC (IN:[1780..1782] in)
        (NP (DT:[1783..1786] the) (NN:[1787..1791] male))))
    (VP (VBD:[1792..1795] led)
      (PP-CLR (TO:[1796..1798] to)
        (NP
          (NP
            (NP (DT:[1799..1802] the) (NN:[1803..1813] disruption))
            (PP (IN:[1814..1816] of)
              (NP (JJ:[1818..1828] testicular)
                (NML (NN:[1829..1833] germ) (NN:[1834..1838] cell))
                (NN:[1839..1853] transformation))))
          (,:[1853..1854] ,)
          (SBAR
            (WHNP-1 (WDT:[1855..1860] which))
            (S
              (NP-SBJ-1 (-NONE-:[1860..1860] *T*))
              (VP
                (ADVP (IN:[1861..1863] in) (NN:[1864..1868] turn))
                (VBD:[1869..1877] resulted)
                (PP-CLR (IN:[1878..1880] in)
                  (NP
                    (NP (DT:[1881..1882] a) (JJ:[1883..1894] significant)
                        (NN:[1896..1905] reduction))
                    (PP (IN:[1906..1908] in)
                      (NP (NN:[1909..1914] sperm) (NN:[1915..1925] production)))))))))))
    (.:[1925..1926] .)))

;sentence 12 Span:1927..2104
;These studies with aromatase inhibitors in the  monkey suggest that these
;compounds have a potential for use as fertility  regulating agents in both
;the male and female primate.
;[1946..1966]:substance:"aromatase inhibitors"
;[2001..2010]:substance:"compounds"
;[2061..2067]:substance:"agents"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1927..1932] These) (NNS:[1933..1940] studies))
      (PP (IN:[1941..1945] with)
        (NP (NN:[1946..1955] aromatase) (NNS:[1956..1966] inhibitors)))
      (PP-LOC (IN:[1967..1969] in)
        (NP (DT:[1970..1973] the) (NN:[1975..1981] monkey))))
    (VP (VBP:[1982..1989] suggest)
      (SBAR (IN:[1990..1994] that)
        (S
          (NP-SBJ (DT:[1995..2000] these) (NNS:[2001..2010] compounds))
          (VP (VBP:[2011..2015] have)
            (NP
              (NP (DT:[2016..2017] a) (NN:[2018..2027] potential))
              (PP (IN:[2028..2031] for)
                (NP
                  (NP (NN:[2032..2035] use))
                  (PP (IN:[2036..2038] as)
                    (NP
                      (ADJP (NN:[2039..2048] fertility)
                            (VBG:[2050..2060] regulating))
                      (NNS:[2061..2067] agents)))
                  (PP-LOC (IN:[2068..2070] in)
                    (NP (CC:[2071..2075] both)
                      (NP (DT:[2076..2079] the) (JJ:[2080..2084] male)
                        (NML-1 (-NONE-:[2084..2084] *P*)))
                      (CC:[2085..2088] and)
                      (NP (JJ:[2089..2095] female)
                        (NML-1 (NN:[2096..2103] primate))))))))))))
    (.:[2103..2104] .)))

;section 13 Span:2108..2152
;PMID: 9365186 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2108..2112] PMID) (::[2112..2113] :) (CD:[2114..2121] 9365186)
        (NN:[2122..2123] -LSB-) (NNP:[2123..2129] PubMed) (::[2130..2131] -)
        (NN:[2132..2139] indexed) (IN:[2140..2143] for)
        (NNP:[2144..2152] MEDLINE-RSB-)))
